As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Eligibility
Sex
ALL
Min age
45 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" .
* no drug contraindications .
* aged between 45 and 75 .
* committed to follow the research procedures, And cooperate with the •implementation of the whole process study .
* the patient understands the relevant treatment process .
* the patient has the ability to give informed consent .
* The patient had not recently taken any medication that affected observation.
* the subjects must meet all the inclusion criteria to be eligible to participate in the study .
Exclusion Criteria:
* mental illness .
* patients with malignant tumors.
* patients with other infectious diseases .
* patients with metabolic bone disease, diabetes and hyperthyroidism.
* patients who cannot actively cooperate in the treatment.
* hypocalcemia.
Primary outcome measure(s)
Knee pain relief — 1,3,6 months OKS function of knee joint at 1,3 and 6 months, VAS pain score at 1,3 and 6 months;
Trial sites (1)
Facility
City
Region
Status
Wuhan Union Hospital
Wuhan
Hubei
Recruiting
More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.